Panavance Therapeutics Inc. is a US, clinical-stage pharmaceutical company established in 2021 by the Swiss-based Avensis Pharma AG, a subsidiary of Ed. Geistlich Söhne AG für Chemische Industrie. Panavance is focused on advancing the development of GP-2250, a novel oncology therapeutic intended to improve outcomes and quality of life for patients with cancer.
With its highly capable team and strong academic and industry partnerships, Panavance is pursuing a rigorous program to bring GP-2250 to patients around the world.
Company Details
- Employees
- 4
- Founded
- 2021
- Address
- 1055 Westlakes Dr,
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- http://www.panavance.com
- HQ
- Berwyn, Pennsylvania
Panavance Therapeutics Inc. Questions
Panavance Therapeutics Inc.'s website is http://www.panavance.com
Panavance Therapeutics Inc.'s LinkedIn profile is https://www.linkedin.com/company/panavance
Panavance Therapeutics Inc. has
4 employees.
View email and phone details for 4
employees at Panavance Therapeutics Inc..
Panavance Therapeutics Inc.'s industry is
Pharmaceutical Manufacturing
Panavance Therapeutics Inc.'s top competitors are
Cognition Therapeutics, Inc.,
Autem Therapeutics,
Kibow Biotech,
Biospectra, Inc.,
Alanis Therapeutics Inc.,
Sfa Therapeutics,
Nutcracker Therapeutics,
Enalare Therapeutics Inc.,
Larimar Therapeutics Inc.,
Uniquity Bio.
Panavance Therapeutics Inc.'s categories are Pharmaceutical Manufacturing
Panavance Therapeutics Inc.'s founding year is 2021
